NOMAD Power Solutions

NMAD · NASDAQ

$3.72−$0.01 (−0.27%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.73

About NMAD

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The company is headquartered in Boca Raton, Florida and currently employs 3 full-time employees. The company went IPO on 2007-09-21. Its product consists of Voyager Eagle, Voyager Falcon, and Voyager Hawk. The company also continues to advance its life sciences portfolio through LIXTE Biotechnology and Liora Technologies, including the development of novel oncology therapeutics and medical technologies. The firm is focused on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100. LB-100 is being tested in clinical trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. Liora Technologies provides Linac for Image Guided Hadron Therapy (LiGHT) system technology, installation support, ongoing maintenance, software upgrades, and clinical/technical training.

Employees: 3
Headquarters: Boca Raton, Florida
Listed: Sep 21, 2007
Sector: Health Care
Industry: Biotechnology
Website: nomadpower.com

Leadership

NOMAD Power Solutions executives
Name	Title	Since	Age
Geordan Pursglove	—	2025	37
Peter Stazzone	—	—	74
Bastiaan van Der Baan	—	2022	54
Lourdes Felix	—	—	57
Michael Holloway	—	—	63
Guy Primus	—	—	—
Jason Sawyer	—	—	54

Similar companies

Companies in the same industry as NOMAD Power Solutions

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.